DK1563846T3 - Endogene reparationsfaktorproduktionsfremmere - Google Patents

Endogene reparationsfaktorproduktionsfremmere

Info

Publication number
DK1563846T3
DK1563846T3 DK03754060.6T DK03754060T DK1563846T3 DK 1563846 T3 DK1563846 T3 DK 1563846T3 DK 03754060 T DK03754060 T DK 03754060T DK 1563846 T3 DK1563846 T3 DK 1563846T3
Authority
DK
Denmark
Prior art keywords
factor production
repair factor
endogenous repair
production promoters
promoters
Prior art date
Application number
DK03754060.6T
Other languages
Danish (da)
English (en)
Inventor
Yoshiki Sakai
Akio Nishiura
Teppei Ogata
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of DK1563846T3 publication Critical patent/DK1563846T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK03754060.6T 2002-10-10 2003-10-09 Endogene reparationsfaktorproduktionsfremmere DK1563846T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002298079 2002-10-10
JP2002318830 2002-10-31
JP2003117604 2003-04-22
PCT/JP2003/012981 WO2004032965A1 (ja) 2002-10-10 2003-10-09 内因性修復因子産生促進剤

Publications (1)

Publication Number Publication Date
DK1563846T3 true DK1563846T3 (da) 2012-12-17

Family

ID=32096713

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03754060.6T DK1563846T3 (da) 2002-10-10 2003-10-09 Endogene reparationsfaktorproduktionsfremmere
DK11010286.0T DK2465537T3 (en) 2002-10-10 2003-10-09 MICROSPHERE INCLUDING ONO-1301

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11010286.0T DK2465537T3 (en) 2002-10-10 2003-10-09 MICROSPHERE INCLUDING ONO-1301

Country Status (10)

Country Link
US (3) US7547715B2 (enExample)
EP (2) EP1563846B1 (enExample)
JP (2) JP4497320B2 (enExample)
AU (1) AU2003272963A1 (enExample)
DK (2) DK1563846T3 (enExample)
ES (2) ES2393321T3 (enExample)
HU (1) HUE029417T2 (enExample)
PT (2) PT1563846E (enExample)
TW (1) TW200413000A (enExample)
WO (1) WO2004032965A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393321T3 (es) 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
WO2005072743A1 (ja) * 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
JP4775663B2 (ja) * 2005-03-30 2011-09-21 地方独立行政法人 大阪府立病院機構 血管新生制御方法
AU2006292021B2 (en) * 2005-09-12 2012-05-31 Es Cell International Pte Ltd. Cardiomyocyte production
KR20080084808A (ko) 2005-11-17 2008-09-19 바이오미메틱 세라퓨틱스, 인크. ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강
EP2311505B1 (en) 2006-02-09 2013-11-06 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
EP3381463A1 (en) 2006-06-30 2018-10-03 BioMimetic Therapeutics, LLC Pdgf-biomatrix compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US20080171972A1 (en) * 2006-10-06 2008-07-17 Stopek Joshua B Medical device package
DK2087890T3 (da) * 2006-10-19 2014-05-19 Ono Pharmaceutical Co Præparat med vedvarende frigørelse til vævsregenereringsterapi
AU2013213727B2 (en) * 2006-10-20 2016-03-17 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2679221B1 (en) * 2006-10-20 2020-09-23 Children's Medical Center Corporation Method to enhance tissue regeneration
WO2008050848A1 (en) * 2006-10-26 2008-05-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
CA2668189C (en) 2006-11-03 2016-01-26 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures comprising a solution of platelet derived growth factor (pdgf) incorporated in a biocompatible matrix
JP5271272B2 (ja) 2006-11-16 2013-08-21 ジェンムス ファーマ インコーポレイティド Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
JP2008195660A (ja) * 2007-02-14 2008-08-28 Kitasato Institute 中枢循環改善薬
CN102014977B (zh) 2008-02-07 2015-09-02 生物模拟治疗有限责任公司 用于牵引成骨术的组合物和方法
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
PL2292231T3 (pl) * 2008-06-23 2016-03-31 Nippon Shinyaku Co Ltd Środek terapeutyczny przeciw zwężeniu kanału kręgowego
CN102231992B (zh) 2008-09-09 2015-05-20 生物模拟治疗公司 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US20100267826A1 (en) * 2009-04-20 2010-10-21 The Board Of Trustees Of The Leland Stanford Junior University Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
EP3167875A1 (en) * 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
NZ601559A (en) 2010-02-22 2014-10-31 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
MX2013001227A (es) * 2010-07-30 2013-04-24 Allergan Inc Compuestos y metodos para reparacion de piel.
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
WO2012112757A2 (en) * 2011-02-17 2012-08-23 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013105997A2 (en) * 2011-02-23 2013-07-18 Allergan, Inc. Compositions and improved soft tissue replacement methods
HUE038653T2 (hu) 2011-03-01 2018-11-28 Pharnext Neurológiai rendellenességek baclofen és acamprosate alapú terápiája
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
US9597436B2 (en) 2012-09-21 2017-03-21 Osaka University Advanced heart failure treatment material as myocardial/cardiovascular regeneration device
US20150272874A1 (en) * 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
US20140142042A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9763911B2 (en) * 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
EP3569249A4 (en) 2016-12-27 2020-11-11 Osaka University PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF REFRACTORY HEART DISEASE
AU2018280264B2 (en) 2017-06-09 2024-07-11 Myoforte Therapeutics, Inc. Compositions and methods for preventing or treating muscle conditions
WO2019023579A1 (en) * 2017-07-27 2019-01-31 The Mclean Hospital Corporation METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF PATHOLOGIES MEDIATED BY NURR1 AND PPARY
WO2019102606A1 (ja) 2017-11-27 2019-05-31 国立大学法人大阪大学 疾患部位特異的リポソーム製剤
JP7233087B2 (ja) * 2019-03-18 2023-03-06 公立大学法人横浜市立大学 抗動脈硬化剤
CN114585364B (zh) 2019-10-28 2025-09-02 塞伊尔特克斯公司 谷氨酸2b受体拮抗剂和σ受体激动剂作为止咳药的用途
CA3167058A1 (en) 2020-02-12 2021-08-19 Cytoagents, Inc. Compositions and methods for treating coronavirus infections
US20230190697A1 (en) * 2020-03-31 2023-06-22 Ensysce Biosciences, Inc. Methods for treating viral infections with nafamostat
KR20220040169A (ko) * 2020-09-23 2022-03-30 (주)아이엠디팜 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 포함하는 경구투여용 제제
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (enExample) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
JPS503362B1 (enExample) 1970-06-10 1975-02-04
JPS5231404B1 (enExample) 1971-04-28 1977-08-15
US3965143A (en) 1974-03-26 1976-06-22 G. D. Searle & Co. 16-Oxygenated prostanoic acid derivatives
US4132738A (en) 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
JPS54130543A (en) * 1978-03-31 1979-10-09 Ono Pharmaceut Co Ltd Prostagladin i2 analog, and its preparation
IT1113341B (it) 1978-03-31 1986-01-20 Ono Pharmaceutical Co Analoghi della 6,9-metano-pgi2
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
US4650804A (en) 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
JPS6130519A (ja) 1984-07-23 1986-02-12 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患治療剤
JPS62134787A (ja) 1985-12-06 1987-06-17 株式会社クボタ 自動販売機の商品払出し装置
CA2100918C (en) * 1992-07-21 1997-01-21 Nobuyuki Hamanaka Oxime derivative
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
JP3162668B2 (ja) 1997-02-04 2001-05-08 小野薬品工業株式会社 ω−シクロアルキル−プロスタグランジンＥ２誘導体
ATE237587T1 (de) 1997-02-10 2003-05-15 Ono Pharmaceutical Co 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
WO1998058911A2 (en) 1997-06-23 1998-12-30 Pfizer Inc. Prostaglandin agonists
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
US6288113B1 (en) * 1997-08-27 2001-09-11 Welfide Corporation Angiogenesis promoters
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US5877211A (en) 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
WO1999033794A1 (en) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES
EP1065233A1 (en) 1998-02-27 2001-01-03 Ono Pharmaceutical Co., Ltd. Carrier polymers migrating into target organs and drug-containing polymers
JP4123568B2 (ja) 1998-05-06 2008-07-23 小野薬品工業株式会社 ６−オキソ−ｐｇｅ１化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンｅ２受容体作働薬
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
JP2000086517A (ja) * 1998-09-16 2000-03-28 Ono Pharmaceut Co Ltd アロディニア治療剤
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
CA2346031A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
JP2000239188A (ja) * 1998-12-22 2000-09-05 Mitsubishi Chemicals Corp 育毛剤
WO2000038667A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
AU2183800A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of dry eye
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
SE9900025D0 (sv) 1999-01-08 1999-01-08 Synphora Ab Method and composition for treatment of female sexual dysfunction
CA2332427A1 (en) 1999-03-16 2000-09-21 Toray Industries, Inc. Prostaglandin ep4 receptor agonist and treatment method
CA2332375A1 (en) 1999-03-16 2000-09-21 Masafumi Isogaya Cervical ripening agent and cervical ripening method
DE60032524T2 (de) 1999-08-10 2007-07-05 Glaxo Group Ltd., Greenford EP4 Rezeptor Ligand und Verwendung gegen neuropathischen Schmerzen, Colon Krebs, HIV und Migräne
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
AP2001002357A0 (en) 1999-12-22 2001-12-31 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis.
EP1132086B1 (en) 2000-01-31 2006-05-31 Pfizer Products Inc. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
CN1366458A (zh) 2000-03-31 2002-08-28 东丽株式会社 毛发生长和毛发形成调节剂
FR2812190B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
US6376533B1 (en) 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
SK5562003A3 (en) 2000-11-27 2004-08-03 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
GB0030541D0 (en) 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
ATE391503T1 (de) 2001-10-23 2008-04-15 Serono Lab Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren
US7335680B2 (en) 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
ES2393321T3 (es) * 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
DK2087890T3 (da) 2006-10-19 2014-05-19 Ono Pharmaceutical Co Præparat med vedvarende frigørelse til vævsregenereringsterapi

Also Published As

Publication number Publication date
JPWO2004032965A1 (ja) 2006-02-09
PT2465537T (pt) 2016-08-03
US8436026B2 (en) 2013-05-07
WO2004032965A1 (ja) 2004-04-22
US20060069018A1 (en) 2006-03-30
DK2465537T3 (en) 2016-09-19
EP1563846A1 (en) 2005-08-17
JP4497320B2 (ja) 2010-07-07
ES2393321T3 (es) 2012-12-20
JP2010120964A (ja) 2010-06-03
EP2465537B1 (en) 2016-06-29
US7547715B2 (en) 2009-06-16
EP1563846A4 (en) 2009-11-04
EP2465537A1 (en) 2012-06-20
JP5287761B2 (ja) 2013-09-11
EP1563846B1 (en) 2012-08-29
US8642630B2 (en) 2014-02-04
TW200413000A (en) 2004-08-01
ES2584606T3 (es) 2016-09-28
US20080299089A1 (en) 2008-12-04
HUE029417T2 (en) 2017-02-28
AU2003272963A1 (en) 2004-05-04
PT1563846E (pt) 2012-11-13
US20130225643A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
DK1563846T3 (da) Endogene reparationsfaktorproduktionsfremmere
DE60317808D1 (de) Beleuchtungsanordnung
NO20044327L (no) Konsentrerte suspensjoner
DE60322789D1 (de) Stromversorgungseinrichtung
FI20020282L (fi) Valaisin
DE50300496D1 (de) Montagemaschine
DE60226122D1 (de) Aufhängungsanordnung
DK1531689T3 (da) Komplet måltidserstatning
FI20021310A0 (fi) Jauhin
DE60313389D1 (de) Scheinwerfer
DE60326616D1 (de) Kapazitiv gekoppelte stromversorgung
DE10256902B4 (de) Kraftstoffzuführvorrichtung
SE0203374L (sv) Hjälpkraftförsörjning
DE60318402D1 (de) Nichtunterbrechende stromversorgungsvorrichtung
DE60236403D1 (de) Tourbillonmechanismus
FI20022005A7 (fi) Liitoskappale
DE50304987D1 (de) Webmaschine
DE50208368D1 (de) Rinnenschuss für strebförderer mit laderampe
DE10393305D2 (de) Liner
ATA14732002A (de) Spannvorrichtung
DE50301369D1 (de) Kuvertierstation für postbearbeitungssysteme
DE50313605D1 (de) Versorgungsleitungsstruktur
NO20023199L (no) Punktmater
ITMI20022179A1 (it) Il manopoliero
DE50310384D1 (de) Strömungsmaschine